SMAD5 antisense RNA 1 (SMAD5-AS1)

SMAD5 antisense RNA 1 (SMAD5-AS1) is a long non-coding RNA situated antisense, and nested within, the SMAD5 gene on human chromosome 5[1]. It is expressed in fetal heart, fetal adrenal glands, and pancreatic tumors, with functional evidence indicating mainly cytoplasmic localization[1][2][4]. SMAD5-AS1 acts as a competing endogenous RNA, regulating critical pathways such as Wnt/β-catenin in a variety of cancer contexts. For example, in diffuse large B cell lymphoma (DLBCL), SMAD5-AS1 suppresses cell proliferation and promotes apoptosis by sponging miR-135b-5p, which leads to increased expression of the tumor suppressor gene APC, ultimately inactivating the Wnt/β-catenin pathway[2][6]. It is downregulated in DLBCL, and its loss is associated with increased tumor cell proliferation[2]. Additionally, SMAD5-AS1 has a regulatory relationship with miR-195 and is implicated in epithelial-mesenchymal transition and metastasis in nasopharyngeal carcinoma, via effects on SMAD5 and related signaling cascades[4]. SMAD5-AS1 is regarded as a promising biomarker and potential therapeutic target in specific cancer types[2][4][6]. No direct pharmacological modulators (drugs) are currently identified for SMAD5-AS1.

Other names

SMAD5-AS1DAMSSMAD5OSSMAD5ASSMAD family member 5 opposite strandSMAD family member 5, antisenseSMAD opposite strand protein10.3 kDa proline-rich protein DAMSSMAD5 antisense gene protein 1SMAD in the antisense orientation

Not directly targeted by drugs; modulates tumor cell proliferation by sponging microRNAs (e.g., miR-135b-5p, miR-195), affecting downstream targets (such as APC) and signaling pathways (Wnt/β-catenin)